Stoke Therapeutics, Inc. (STOK) stock
STOKNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 6/30173% above fair value
$26.41−0.22 (-0.83%)
Close on Nov 17, 2026Market cap $1.70BP/E –Yield –
Stoke Therapeutics EV/EBITDA
EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.
Stoke Therapeutics's EV/EBITDA was 52.4× on Jan 30, 2026.
EV/EBITDA at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Jan 30, 2026 | 52.4× | −2.8 |
| 2025 | Dec 31, 2025 | 55.2× | – |
See a number that looks wrong?